VPS11 Activators
VPS11 Activators are a specialized set of chemical compounds that enhance the functional activity of VPS11 through indirect interactions with various cellular signaling pathways. For example, Forskolin and Epigallocatechin gallate indirectly amplify VPS11 activity by modifying secondary messenger systems and kinase activity. Forskolin raises cyclic AMP levels, which sequentially activates PKA, potentially influencing substrates that interact with VPS11, thus enhancing its role in vesicular trafficking. Epigallocatechin gallate, a kinase inhibitor, may alleviate negative regulation on VPS11, indirectly promoting its function in endosomal-lysosomal sorting. Moreover, Sphingosine-1-phosphate and Thapsigargin affect lipid and calcium signaling, respectively, pathways that are vital for the vesicle trafficking and fusion events VPS11 is implicated in. Specifically, Thapsigargin increases intracellular calcium, which can stimulate VPS11's vesicle fusion activity due to the pivotal role of calcium in such processes.
Furthermore, the functional activity of VPS11 is indirectly influenced by compounds such as U73122, NSC 23766, and ML141, which impact phospholipase C activity, Rac1 activation, and Cdc42-mediated cytoskeletal dynamics. These changes in cellular processes can enhance VPS11's role in vesicle formation and trafficking. Y-27632, LY294002, and Wortmannin modulate actin cytoskeleton organization and the PI3K/AKT pathway, respectively, which could result in an enhanced endocytic pathway, thus facilitating VPS11's essential function in membrane trafficking. Additionally, PD 98059 and SB203580, by inhibiting the MEK and p38 MAPK pathways, may shift the signaling balance to favor the enhancement of VPS11's role in vesicle formation and endosome-lysosome fusion. Collectively, these VPS11 activators, through their targeted effects on cellular signaling, facilitate the enhancement of VPS11-mediated functions without upregulating its expression or requiring direct activation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular cAMP levels, which activates PKA. PKA then phosphorylates various substrates, potentially including those that interact with VPS11, thereby enhancing VPS11's role in vesicular trafficking and autophagy. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate inhibits a range of kinases, possibly reducing negative regulatory influences on VPS11, thus indirectly promoting VPS11's function in endosomal-lysosomal sorting and fusion processes. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate binds to its receptors, which can trigger downstream signaling cascades influencing cytoskeletal rearrangements. This can augment VPS11's activity by facilitating the vesicle transport and fusion events VPS11 is involved in. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase, leading to increased cytosolic calcium levels, which may enhance VPS11's vesicular trafficking functions due to calcium's role in vesicle fusion. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 disrupts Rac1 activation by inhibiting its interaction with GEFs, which could lead to an alteration in actin cytoskeleton dynamics, indirectly influencing vesicle formation and potentially enhancing VPS11's role in vesicular trafficking. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a Cdc42 inhibitor, potentially modulating cytoskeletal organization and vesicle trafficking. By affecting these cellular processes, ML141 may indirectly enhance VPS11's function in vesicular formation and trafficking. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that modulates actin cytoskeleton organization and cell motility. This can lead to enhanced vesicular trafficking and endosome dynamics, which are processes VPS11 is critical for. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which alters the PI3K/AKT pathway. This may enhance VPS11 activity by modulating the endocytic pathway and vesicle formation, as VPS11 is essential for membrane trafficking. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002, which could lead to an indirect enhancement of VPS11 function by affecting the endocytic pathway and membrane trafficking processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor, which may influence the ERK/MAPK pathway. By modulating this pathway, PD 98059 could indirectly affect the vesicular trafficking and fusion events in which VPS11 is involved. | ||||||